Similarly, the efficacy of anti-PD-1 inhibitor pembrolizumab (Keytruda) was investigated in a phase 2 study for second-line treatment in advanced HCC patients following sorafenib failure. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.